

Laboratory Service Report

1-800-533-1710

REPORTED 11/19/2011 13:27

MCR

MCR MCR

Patient Name REPORTVALIDATION, AUTOMATION DN	Patient ID RVDNPLB062	Age 40	Gender	Order # RVDNPLB062
Ordering Phys	INVENTEDUOZ	140		DOB
Client Order #	Account Information			01/01/1971 Report Notes
RVDNPLB062				
Collected	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE			
Printed 11/21/2011 11:02	ROCHESTER,MN 55901			

Reference Perform Test Flag Results Unit Value Site*

HLAB 1502 Genotype, Saliva

HLA-B 1502 Result

HLA-B 1502 Reviewed by

HLA-B 1502 Interpretation

Negative

Jamie Bruflat

The HLA-B*1502 allele was not found. This patient is at no greater risk than the general population for the development of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS) when treated with carbamazepine, fosphenytoin, or phenytoin. A negative result does not preclude the development of SJS and cannot substitute for clinical vigilance whenever carbamazepine, fosphenytoin, or phenytoin therapy is administered. Therapy should be discontinued immediately and permanently should TEN or SJS develop.

The HLA-B genotyping is performed by allele-specific amplification to verify the presence or absence of the HLA-B*1502 allele and to eliminate confounding alleles. In addition to carbamazepine, fosphenytoin, or phenytoin, some studies have also suggested a connection between HLA-B*1502 positivity and adverse reactions to lamotrigine an anticonvulsant used for treating seizure disorders. Laboratory developed test.

* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
-----	---	--

Patient Name REPORTVALIDATION, AUTOMATION DN	Collection Date and Time 11/18/2011 11:30	Report Status Final
Page 1 of 1		** End of Report **